Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: An institutional experience in Turkey

Journal of B.U.ON.

Volumn 19, Issue 1, 2014, Pages 164-170

  Kucukoner, Mehmet ^a   Kaplan, Mehmet Ali ^a   Inai, Ali ^a   Urakci, Zuhat ^a   Abakay, Ozlem ^a   Tanrikulu, Abdullah Cetin ^a   Abakay, Abdurrahman ^a   Sen, Hatice Selim ^a   Turkcu, Gul ^a   Senyigit, Abdurrahman ^a   Buyukbayram, Huseyin ^a   Isikdogan, Abdurrahman ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Malignant pleural mesothelioma; Prognosis; Treatment

Indexed keywords

CISPLATIN; GEMCITABINE; HEMOGLOBIN; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DECORTICATION; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; EXTRAPLEURAL PNEUMONECTOMY; FEMALE; HISTOPATHOLOGY; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; LEUKOCYTOSIS; LEUKOPENIA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPATHY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TURKEY (REPUBLIC);

ADULT; AGED; AGED, 80 AND OVER; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME; TURKEY;

EID: 84898925475     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-308.
2. Moore AJ, Parker RJ, Wiggins J. Malignant pleural mesothelioma. Orphanet J Rare Dis 2008;19:1-11.
3. Takagi A, Hirose A, Nishimura T et al. Induction of mesothelioma in p53 +/- mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008;33:105-116. (Pubitemid 351340768)
4. Yaziaoǧlu S. Pleural calcification associated with exposure to Chrysotile asbestos in Southeast Turkey. Chest 1976;70:43-47.
5. Jones JSP. Pathology of mesothelioma. Eur Respir Rev 1993;3:22-24. (Pubitemid 23135315)
6. Herndon J, Green M, Chahinian A et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731. (Pubitemid 28130949)
7. Pass HI, Vogelzang NJ, Hann SM, Michele Carbone M. Benign and malignant mesothelioma. In: Devita VT, Lawrence T, Rosenberg SA (Eds): Cancer: Principies and Practise of Oncology (9th Edn.). Philadelphia Lippincott Williams & Wilkins,2011, pp 2059-2063.
8. Alolayan A, Saadeddin A, Bamousa A, Jazieh AR. Treatment of malignant pleural mesothelioma. Ann Thor Med 2010;5:71-75.
9. Kaufman AJ, Flores RM. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2011;12:201-216.
10. Treasure T, Lang-Lazdunski L, Waller D et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-772.
11. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644. (Pubitemid 46606305)
12. Nowak AK, Byrne MJ, Williamson R et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491-496.
13. Byme MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25-30. (Pubitemid 29022374)
14. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655. (Pubitemid 13149996)
15. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990;8:147-159. (Pubitemid 20350387)
18. Hanna L, Macbeth F. Mesothelioma. Hanna L, Crosby T, Macbeth F (Eds): Practical Clinical Oncology (1st Edn). Cambridge University Press, 2012, pp 289-294.
19. Carkanat AI, Abdurrahman A, Abakay O, Cengizhan S, Selimoglu SH, Senyigit A. The incidence of mesothelioma has not decreased for the last twenty years in Southeast region of Anatolia. Afr Health Sci 2011;11:346-352.
20. Abakay A, Tanrikulu AC, Kaplan MA et al. Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma Lung India 2011;28:267-271.
21. Rush VW, Venkatraman E. The Importance of Surgical Staging in the treatment of Malignant Pleural Mesothelioma J Thorac Cardiovasc Surg 1996;111:815-826. (Pubitemid 26118862)
22. Calevrezos A, Koschei G, Husselmann H et al. Malignant mesothelioma of the pleura: A prospective study of 132 patients from 1981-1985. Klin Wochenschr 1988;66:607-613.
23. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection Margins, Extrapleural Nodal Status and Cell Type Determine Postoperative Long-Time Survival In Trimodality Therapy of Malignant Pleural Mesothelioma: Results In 183 Patients. J Thorac Cardiovasc Surg 1999; 117: 54-65. (Pubitemid 29022249)
24. Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management Oncology (Williston Park) 2002;16:907-913.
25. Rush W. Diffuse malignant mesothelioma. In: Shields TW (Ed): General Thoracic Surgery (5th Edn). Lippincott Williams & Wilkins, Philedelphia, 2000, ch 65, pp 767-182.
26. Herndon JE, Green MR, Chahinian P et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and leukemia group B. Chest 1998;113:723-731. (Pubitemid 28130949)
27. Ordonez NG. Imunohistochemical diagnosis of epithelioid mesotheliomas: A critical review of old markers, new markers. Hum Pathol 2002; 33:953-967.
28. Huncharek M, Smith K. Extrathoracic lymph node metastases in malignant pleural mesothelioma. Chest 1988;93:443-444.
29. Burt BM, Rodie SJ, Tilleman TR et al. Circulated and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011;117:5234-5244.
30. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: A Lung Cancer Study Group Trial. J Thorac Cardiovasc Surg 1991;102:1-9.
31. Elkiran ET, Kaplan MA, Sevinc A et al. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Med Oncol 2012;29:3147-3154.
32. Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-626.
33. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: Who benefits ? Chest 1995;107:345-350.
34. Maziak DE, Gagliardi A, Haynes AE, Mackay JA, Evans WK. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005;48:157-169.
35. Castagneto B, Zai S, Dongiovanni D et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005;28:223-226. (Pubitemid 40800471)
36. Lee C, Murray N, Anderson H, Bouttell E. Outcomes with platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice. J Thorac Oncol 2007;2:606-613.
37. Abakay A, Abakay O, Tanrikulu AC et al. Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci 2013;17:19-24.